Apoptosis

Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024

Retrieved on: 
четверг, мая 23, 2024
MSD, Pembrolizumab, Merck & Co., Patient, Oxidative stress, TPS, Trastuzumab, Science, HER2, Proteostasis, Tumor microenvironment, FDA, Endometrial cancer, Safety, Breast cancer, ADC, Senior, Headquarters, LEAP, Research, Deep, Cancer, Drug discovery, ASCO, Merck, PRISM, Society, Apoptosis, Hepatocellular carcinoma, Differentiable function, Inflammation, Hypoxia, Annual general meeting, Pharmaceutical industry

TOKYO, May 23, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4.

Key Points: 
  • TOKYO, May 23, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains with the aim of contributing to the cure of cancers.
  • (1) KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

Retrieved on: 
среда, мая 22, 2024
Partnership, Patient, Discovery, CRM, Boehringer Ingelheim, Cancer, EUR, Death, Acquisition, Apoptosis, Boehringer, Pharmaceutical industry

Nantes, France - Ingelheim, Germany - 22 May 2024, 7:30am CET - Today OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Boehringer Ingelheim announced a major expansion of their partnership.

Key Points: 
  • Nantes, France - Ingelheim, Germany - 22 May 2024, 7:30am CET - Today OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Boehringer Ingelheim announced a major expansion of their partnership.
  • Two new projects to develop first-in-class treatments will be added to the ongoing anti-SIRPα immuno-oncology programs.
  • A new preclinical program will be launched to develop immune-cell activating treatments based on OSE’s cis-targeting1 anti-PD1/cytokine platform via an asset acquisition.
  • Cancer accounts for nearly 10 million deaths and for many cancer patients there are no or only limited treatment options.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease

Retrieved on: 
четверг, мая 16, 2024
Medical laboratory, Partnership, Learning, Doctor of Philosophy, Parasitism, Pathology, Patent, Malaria, Apoptosis, Artemisinin, IND, Ocean Biomedical, Vaccine, Plasmodium falciparum, Brown University, MD, Death, Research, Alpert Medical School, Therapy

Kurtis’ novel approach can cause parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis.

Key Points: 
  • Kurtis’ novel approach can cause parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis.
  • This expands patent protection for Dr. Kurtis’ novel discoveries at a time when the most common strains of malaria are showing signs of growing resistance to current Artemisinin-based drugs.
  • Ocean is working to optimize the formulation of its vaccine and therapeutic antibody prior to IND submission and first-in-humans testing.
  • Malaria is the greatest single-agent killer of children on the planet, killing approximately 627,000 individuals in 2022.

AriBio Receives IND Approval from China’s NMPA for POLARIS-AD, a Phase 3 Trial for the Treatment of Early Alzheimer’s Disease

Retrieved on: 
вторник, мая 14, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Patient, CSF, Plasma, Investigational New Drug, NMPA, POLARIS, Polaris, Apoptosis, Mini–Mental State Examination, Clinical trial, Geriatric Depression Scale, IND, Disease, Safety, GDS, ClinicalTrials.gov, Biomarker, Attention, Cerebrospinal fluid, PDE5, CDE, Pharmaceutical industry

The Phase 3 clinical trial will enroll early AD patients at up to 20 clinical trial centers in China with consistent eligibility criteria compared to other countries that are also enrolling patients.

Key Points: 
  • The Phase 3 clinical trial will enroll early AD patients at up to 20 clinical trial centers in China with consistent eligibility criteria compared to other countries that are also enrolling patients.
  • With the inclusion of China, a significant player in the global pharmaceutical market, in the Phase 3 clinical trial development of AR1001, AriBio continues to expand its reach and impact in the fight against Alzheimer's disease.
  • AR1001 is a phosphodiesterase-5 (PDE5) inhibitor being developed as an investigational oral agent for the treatment of Alzheimer’s disease.
  • AR1001-ADP3-US01 ( NCT05531526 ) is a Phase 3 double-blind, randomized, placebo-controlled, multi-center trial evaluating the efficacy and safety of AR1001 in patients with early Alzheimer’s disease.

Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis

Retrieved on: 
среда, мая 8, 2024
Neuroprotection, Inflammation, Hospital, Safety, OCS, Diabetic retinopathy, Apoptosis, Optic neuritis, AON, IND, Disease, Patient, Paratriathlon, Geographic atrophy, Optic nerve, Neuron, Glaucoma, Ophthalmology, Neuro, Pharmaceutical industry

The Phase 2 ACUITY study is evaluating once-daily OCS-05 intravenous infusion in patients with AON.

Key Points: 
  • The Phase 2 ACUITY study is evaluating once-daily OCS-05 intravenous infusion in patients with AON.
  • OCS-05 has been granted orphan drug designation in both the United States and Europe, highlighting the importance of this unmet medical need.
  • In the meantime, we keep on working towards an IND submission for OCS-05 in the U.S. in 2024.
  • While corticosteroids are used to shorten the attack, there is no approved therapy for AON and unmet needs remain for therapies that can prevent vision loss after an acute episode of optic neuritis.

US Medical Innovations Secures FDA Clearance for Canady Helios Cold Plasma™ Ablation System

Retrieved on: 
вторник, мая 7, 2024
Research, Robotics, Oncology, Medical Devices, Technology, Artificial Intelligence, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Risk, Innovation system, Doctor of Philosophy, SMC, RNS, Sheba Medical Center, Medicine, RMC, Oncology nursing, Purdue University, Canady, ROS, Surgical oncology, Entrepreneurship, Plasma, Johns Hopkins University, Patient, Multi, Argon, Safety, George Washington University, Microsoft Access, Cell death, Survival, IDE, University of Massachusetts, Treatment, Multimedia, Reactive nitrogen species, Engineer, CHCP, University, Apoptosis, FACS, Field line, Airline, Rush University Medical Center, Reactive oxygen species, Nursing

US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.

Key Points: 
  • US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.
  • The CHCP system consists of the Canady Helios Cold Plasma XL-1000 CP Smart Electrosurgical Generator, Canady Helios Cold Plasma Ablators, Foot Pedal and Trolley Cart.
  • The Canady Helios Cold Plasma™ System introduces a novel approach to soft tissue ablation using plasma.
  • For more information on US Medical Innovation’s products and technology please visit: www.usmedinnovations.com .

PLK Targeted Therapies Market & Clinical Trials 2024: Onvansertib Leading the Way in PLK1 Inhibition, Pioneering Breakthroughs in Small Cell Lung Cancer and Chronic Myelomonocytic Leukemia Treatment - ResearchAndMarkets.com

Retrieved on: 
вторник, мая 7, 2024
Health, Clinical Trials, Cytokinesis, Immunotherapy, Cancer, Chronic myelomonocytic leukemia, Inflammation, Disorder, Safety, Breast cancer, Viral, Apoptosis, SCLC, Cell proliferation, Research, Cell cycle, Carcinoma, DNA, Mitosis, Indication, Patient, Rheumatoid arthritis, Hepatitis B virus, Virus, Proteolysis targeting chimera, Multiple sclerosis, HIV, Messenger, PLK, Lupus, Genome, Biomarker, Medicine, PLK1, DA, HBV, Pharmaceutical industry

The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • Onvansertib, a PLK1 inhibitor developed by Cardiff Oncology, is currently the most advanced candidate in clinical trials.
  • The progression of these candidates through the pipeline reflects the growing interest and confidence in PLK targeted therapies.
  • In conclusion, PLK targeted therapies are a rapidly developing field with revolutionary promise across a wide range of disease areas.

Sampling Human Ships its First Kits for Cellular Analysis to Early Access Customers and Releases an App Note with BMG LABTECH

Retrieved on: 
понедельник, мая 6, 2024
Research, Medical Devices, Genetics, Health Technology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, BMG, Cell biology, Single-cell analysis, Luminescence, Apoptosis, Microplate, Organoid, Partnership, Sampling, University, Early access, CBEC, BioRxiv, Student, Drug discovery

Sampling Human, Inc. , a techbio company developing single cell technologies, announces the delivery of its Apoptosis (Anti-PS) Biocytometry Kits to Early Access customers.

Key Points: 
  • Sampling Human, Inc. , a techbio company developing single cell technologies, announces the delivery of its Apoptosis (Anti-PS) Biocytometry Kits to Early Access customers.
  • In addition, Sampling Human has partnered with BMG LABTECH to release an application note pairing their kits with BMG LABTECH microplate readers.
  • Daniel Georgiev, co-founder and chief executive officer of Sampling Human, will be speaking on applications for the technology at the SynBioBeta conference.
  • “At Sampling Human, we recognize the great lengths scientists go to today in order to obtain high-quality single-cell data,” said Daniel Georgiev.

Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry

Retrieved on: 
среда, мая 1, 2024
Conditional sentence, Brain, Drug, Enzyme, Patient, Bone marrow, Acetone, Organelle, Soybean, Inflammation, Methane, Protein, Cell, Laboratory, Mineral, Pregnancy, Blood, Yolk, Health, Apoptosis, Human body, Death, Research, Vitamin, Water, Carbon, Functional food, Phospholipid, Kaifeng, Dietary fiber, Disease, Convalescence, Agonal respiration, Human, Mitochondrion, SISI, Food, Medicine, PC, Golgi, Carbohydrate, Nutrient, Beauty, Signal transduction, Temperature, Ageing, Microsome, Lipid, Cell damage, Malabsorption, Growth, Fats, Phosphorus

Cells are the basic units of life, and the health and vitality of cells directly affect the health of the entire body.

Key Points: 
  • Cells are the basic units of life, and the health and vitality of cells directly affect the health of the entire body.
  • Cells need to continuously obtain nutrients from the external environment to support their normal growth, division and metabolic activities.
  • When cells receive sufficient and balanced nutrients, they can maintain optimal conditions, perform various life activities, and maintain cell health.
  • The layout of the three major fields will create natural active water phospholipids into a super new category in the health industry.

PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers

Retrieved on: 
четверг, апреля 25, 2024
Phases of clinical research, Paclitaxel, Cell, Safety, Pharmacokinetics, Drug development, PP2A, Apoptosis, Index, Conference, PDAC, MTD, Patient, Principal, OC, AACR, Curie Institute (Paris), Pharmaceutical industry

PEP-010 is a pro-apoptotic agent which has demonstrated a good safety and tolerability profile and first signals of efficacy in the CLEVer-PEPtide Phase Ia dose escalation clinical trial.

Key Points: 
  • PEP-010 is a pro-apoptotic agent which has demonstrated a good safety and tolerability profile and first signals of efficacy in the CLEVer-PEPtide Phase Ia dose escalation clinical trial.
  • Four sites in France are currently recruiting: Institut Curie, Gustave Roussy, Centre François Baclesse and Institut de Cancérologie de l'Ouest.
  • “We are thrilled to see the first patients dosed in this Phase Ib trial.
  • Christophe Le Tourneau, Medical Oncologist at Institut Curie, Head of the Department of Drug Development and Innovation (D3i), and Principal Investigator of the CLEVer-PEPtide trial.